Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Mr. Alex G. Howarth

Executive Officer

Ms. Tina E. Ventura

Chief Investor Relations Officer

Mr. Brian J. Lynch J.D.

Senior Vice President & General Counsel

Ms. Mardi C. Dier

Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer & Senior Vice President

Dr. Kianoush  Motesharei Ph.d.

Senior Vice President of Business & Corporate Development

Mr. Clint  Wallace

Chief Human Resources Officer

Mr. Edward  Chiang

Senior Vice President of Clinical & Technical Operations

Mr. Ronald  Filippo

Chief Information Officer

Mr. William J. Sibold

Chief Executive Officer, President & Director

Dr. Rebecca A. Taub M.D.

Founder, Chief Medical Officer, President of Research & Development and Director

Биотехнологии

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. Структура на управлението

Информация за управлението